Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Clinical trial NCT04957212 · COMPLETED

Trial details

NCT number: NCT04957212
Sponsor: Cinnagen
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2018-08-11
Primary completion: 2020-05-27
Enrollment: 214

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.